I want to know the answer to the following question:
What can be used to evaluate new approval processes?
All the background I'm provided with is that "Others have argued that excessive regulation suppresses therapeutic innovation, and that the current cost of regulator-required clinical trials prevents the full exploitation of new genetic and biological knowledge for the treatment of human disease.". Is that enough to answer the question?
Answer: no